SCHEDULE: Alyeska Investment Group Discloses 9.9% Stake in Cabaletta Bio

Alyeska Investment Group, L.P. and its affiliates have disclosed a 9.9% beneficial ownership stake in Cabaletta Bio, Inc., totaling 8,904,367 shares.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have reported beneficial ownership of 8,904,367 shares of Cabaletta Bio, Inc. common stock.
• This represents 9.9% of the total outstanding common stock of Cabaletta Bio, Inc.
• The ownership includes 4,800,000 shares of common stock and warrants exercisable for up to 4,104,367 additional shares as of June 30, 2025.
• The percentage calculation is based on 89,943,101 outstanding common shares of Cabaletta Bio, Inc., as reported in their Prospectus filed on June 12, 2025.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a substantial 9.9% beneficial ownership by Alyeska Investment Group, a known institutional investor, suggests a vote of confidence in Cabaletta Bio, Inc. This can be interpreted as a positive signal by the market, although the filing itself does not contain operational or financial performance data.

Positives

• A significant stake of 9.9% by an institutional investor like Alyeska Investment Group may signal confidence in Cabaletta Bio, Inc.'s future prospects.
• The investment includes both direct shares and warrants, indicating a long-term interest and potential for increased ownership up to the 9.9% cap.

Risks

• No specific risks related to Cabaletta Bio, Inc.'s operations or financial health are disclosed in this ownership filing.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding Cabaletta Bio, Inc.'s future operations or financial performance, as it is solely a disclosure of beneficial ownership.

Management Comments

• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Cabaletta Bio, Inc.

Industry Context

The disclosure of a significant stake by an investment group in a biotechnology company like Cabaletta Bio, Inc. is a common occurrence in the industry, where institutional investors often take positions in companies with promising pipelines or technologies. This type of filing provides transparency on major shareholder positions.

Comparison to Industry Standards

• A 9.9% stake is a substantial position for an institutional investor in a publicly traded company, often indicating a high level of conviction in the company's long-term value proposition.
• While specific comparable companies or projects are not mentioned in this filing, such a stake by a reputable investment group like Alyeska Investment Group is generally viewed positively within the investment community, aligning with typical institutional investment strategies in the biotech sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may increase investor confidence and potentially influence stock price positively.
• Company Management: Awareness of a large, non-control-seeking shareholder.

Next Steps

• This filing does not outline any specific future actions or milestones for Cabaletta Bio, Inc. or the reporting persons beyond the ongoing ownership.

Key Dates

Recommendation

The filing indicates a significant vote of confidence from a major institutional investor, Alyeska Investment Group, which has acquired a 9.9% stake in Cabaletta Bio. This substantial ownership, including both direct shares and warrants, suggests a positive long-term outlook from a sophisticated market participant. While this is a positive signal, the filing itself does not provide new operational or financial performance data for Cabaletta Bio, Inc. that would warrant a 'buy' recommendation. It primarily confirms a large investor's position. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive signal from Alyeska's investment while awaiting further company-specific performance updates.

Keywords

Cabaletta Bio, Alyeska Investment Group, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Institutional Investor, Biotechnology